More than 1,000,000 patients are currently being treated with Dupixent globally. 1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

The following is a summary of “Integrative epidemiology and immuno-transcriptomics uncover a risk and potential mechanism for ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Eczema affects an estimated 20 per cent of children and 11 per cent of adults in Singapore. In its moderate to severe form, ...

Get detailed information on Dupilumab, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

A major news story from Sanofi this month is that "The European Medicines Agency has approved Dupixent (dupilumab) to treat ...

A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...

The findings of this study show that Nevisense, which utilizes electrical impedance spectroscopy (EIS) to assess skin barrier integrity, can effectively track changes in skin barrier function in ...

Second Phase 3 Clinical Trial Again Shows Dupilumab Lessens Disease in COPD Patients With Type 2 Inflammation May 20, 2024 — Chronic obstructive pulmonary disease patients with type 2 ...

Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.